Security key
29405E208
Enveric Biosciences, Inc. - Common Stock, $0.01 par value (ENVB)
CUSIP: 29405E208
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock, $0.01 par value
- Shares outstanding
- 1,022,530
- Total 13F shares
- 505,777
- Share change
- +17,550
- Total reported value
- $307,294
- Price per share
- $0.63
- Number of holders
- 17
- Value change
- -$15,307
- Number of buys
- 9
- Number of sells
- 8
Report period
Q2 2024
Institutions
17
Top holders
10
ENVB full security history
Newer quarter: Q3 2024
Previous quarter: Q1 2024
Enveric Biosciences, Inc. SEC filings
Enveric Biosciences, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 29405E208
Recent filing periods:
Top shareholders of ENVB - Enveric Biosciences, Inc. - Common Stock, $0.01 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| AdvisorShares Investments LLC |
13F
|
Company |
23%
|
238,833
|
$238,833 | — | 31 Mar 2024 | |
| HRT FINANCIAL LP |
13F
|
Company |
6.2%
|
63,026
|
$63,000 | — | 31 Mar 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
3.9%
|
40,104
|
$40,104 | — | 31 Mar 2024 | |
| Virtu Financial LLC |
13F
|
Company |
3.3%
|
33,835
|
$34,000 | — | 31 Mar 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
2.9%
|
29,578
|
$29,578 | — | 31 Mar 2024 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
1.8%
|
18,247
|
$18,247 | — | 31 Mar 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
1.8%
|
18,198
|
$18,198 | — | 31 Mar 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
1.5%
|
15,397
|
$15,397 | — | 31 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.3%
|
13,118
|
$13,118 | — | 31 Mar 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
1.2%
|
12,277
|
$12,277 | — | 31 Mar 2024 | |
| UBS Group AG |
13F
|
Company |
0.49%
|
4,983
|
$4,983 | — | 31 Mar 2024 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0.03%
|
273
|
$273 | — | 31 Mar 2024 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0.01%
|
150
|
$150 | — | 31 Mar 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.01%
|
100
|
$100 | — | 31 Mar 2024 | |
| NATIONAL BANK OF CANADA /FI/ |
13F
|
Company |
0.01%
|
70
|
$63 | — | 31 Mar 2024 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
37
|
$37 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
1
|
$1 | — | 31 Mar 2024 | |
| Carter Julian Ward |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
744,429
|
— | — | 19 Jan 2022 | |
| Thompson Bradley George |
3/4/5
|
Director |
—
class O/S missing
|
53,160
|
— | — | 16 Sep 2021 | |
| Avani Kanubaddi |
3/4/5
|
President and COO |
—
class O/S missing
|
48,346
|
— | — | 25 Jan 2023 | |
| Jillian Marie Hagel |
3/4/5
|
Vice President of Innovation |
—
class O/S missing
|
35,802
|
— | — | 25 Jan 2023 |
Institutional Holders of Enveric Biosciences, Inc. - Common Stock, $0.01 par value (ENVB) as of Q2 2024
As of 30 Jun 2024,
Enveric Biosciences, Inc. - Common Stock, $0.01 par value (ENVB) was held by
17 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
505,777 shares.
The largest 10 holders included
AdvisorShares Investments LLC, GEODE CAPITAL MANAGEMENT, LLC, UBS Group AG, BlackRock Inc., VANGUARD GROUP INC, TWO SIGMA SECURITIES, LLC, Virtu Financial LLC, Tower Research Capital LLC (TRC), HRT FINANCIAL LP, and OSAIC HOLDINGS, INC..
This page lists
17
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
17
Q2 2024 holders
17
Holder diff
0
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.